ISCA2 and nonpapillary renal cell carcinoma: To investigate the feasibility of ISCA2 inhibition as a therapeutic strategy for ccRCC, we used #25 as a probe compound based on its acceptable drug-like properties (bioavailability F = 27.3%; half-life T1/2: 3.61 h, not shown).